AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
Lenacapavir Sodium
6 registrations across 3 African markets— 6 active
Markets with Lenacapavir Sodium
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Lenacapavir Gilead 464 mg solution for injection Solution for Injection. | 🇷🇼Rwanda | Patheon Italia S.p.A. | active | Dec 2030 |
| Lenacapavir Gilead 300 mg film-coated tablets TABLES | 🇷🇼Rwanda | ROTTENDORF PHARMA GMBH | active | Dec 2030 |
| Lenacapavir Gilead 300 mg Film-Coated Tablets Film Coated Tablets | 🇿🇲Zambia | Gilead Sciences Ireland UC | active | Nov 2030 |
| Lenacapavir Gilead 464 mg Solution for Injection Solution for injection | 🇿🇲Zambia | Gilead Sciences Ireland UC | active | Nov 2030 |
| Lenacapavir Gilead 464 mg solution for injection Solution for injection | 🇹🇿Tanzania | Gilead Sciences Ireland UC | active | — |
| Lenacapavir Gilead Film Coated Tablet | 🇹🇿Tanzania | Gilead Sciences Ireland UC | active | — |
Lenacapavir Sodium in Africa — Regulatory Overview
Lenacapavir Sodium is registered across 3 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Rwanda, Tanzania, Zambia. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 6 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.